Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been investigated for their potential to alleviate peripheral neuropathy, especially in the context of diabetic neuropathy and chemotherapy-induced peripheral neuropathy. The rationale for their use is based on their anti-inflammatory properties and their role in maintaining neuronal membrane integrity. Several preclinical studies in animal models have demonstrated that omega-3 supplementation can reduce neuropathic pain behaviors and nerve damage, likely through modulating inflammation and oxidative stress.

In humans, the evidence is limited but growing. Small clinical trials and pilot studies have suggested that omega-3 supplementation may help reduce symptoms such as numbness, tingling, and pain in patients with peripheral neuropathy. For example, a 2017 pilot study in patients with chemotherapy-induced neuropathy found that omega-3 supplementation reduced neuropathic symptoms compared to controls. Another small randomized trial in diabetic patients reported modest improvements in neuropathic pain scores with omega-3 supplementation. However, these studies are generally small, short-term, and sometimes lack rigorous controls.

Overall, while there is a plausible biological mechanism and some preliminary clinical evidence, large-scale, well-controlled human trials are lacking. Thus, the evidence supporting omega-3 for peripheral neuropathy is limited and rated as 2/5 for scientific support.

More about Omega-3
More about Peripheral Neuropathy

Other ingredients used for Peripheral Neuropathy

Other health conditions supported by Omega-3

Products containing Omega-3